[1]赵刚刚,张鸿毅,肖克兵,等.自然杀伤细胞2组成员A、程序性死亡因子配体1表达检测对PD-L1阻断免疫治疗肌层浸润性膀胱癌反应性的预测价值[J].陕西医学杂志,2024,(2):252-256.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.023]
　ZHAO Ganggang,ZHANG Hongyi,XIAO Kebing,et al.Value of NKG2A and PD-L1 expression in predicting responsiveness of PD-L1 blocking immunotherapy for myometrial invasive bladder cancer[J].,2024,(2):252-256.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.023]
点击复制

自然杀伤细胞2组成员A、程序性死亡因子配体1表达检测对PD-L1阻断免疫治疗肌层浸润性膀胱癌反应性的预测价值
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年2期
页码:
252-256
栏目:
临床检验
出版日期:
2024-02-05

文章信息/Info

Title:
Value of NKG2A and PD-L1 expression in predicting responsiveness of PD-L1 blocking immunotherapy for myometrial invasive bladder cancer
作者:
赵刚刚; 张鸿毅; 肖克兵; 杨 辉; 李子峰; 赵华才
(西安医学院第一附属医院泌尿外科,陕西 西安 710077)
Author(s):
ZHAO Ganggang; ZHANG Hongyi; XIAO Kebing; YANG Hui; LI Zifeng; ZHAO Huacai
(Department of Urinary Surgery,First Affiliated Hospital of Xi'an Medical University,Xi'an 710077,China)
关键词:
膀胱癌;  肿瘤直径;  自然杀伤细胞2组成员A;  程序性死亡因子配体1;  免疫治疗;  反应性
Keywords:
Bladder cancer;  Tumor diameter;  Natural killer cell group 2 member A;  Programmed death factor ligand 1;  Immunotherapy;  Reactivity
分类号:
R 737.14
DOI:
DOI:10.3969/j.issn.1000-7377.2024.02.023
文献标志码:
A
摘要:
目的:探究自然杀伤细胞2组成员A(NKG2A)及程序性死亡因子配体1(PD-L1)表达检测对PD-L1阻断免疫治疗肌层浸润性膀胱癌反应性的预测价值。方法:选取100例肌层浸润性膀胱癌患者作为研究对象,对其行PD-L1阻断免疫治疗后,根据治疗反应性将其分为缓解组和未缓解组; 对缓解组患者随访3个月,将其分为复发组和未复发组。比较两组患者NKG2A和PD-L1在CD4+和CD8+上的表达水平,采用ROC曲线分析NKG2A和PD-L1预测膀胱癌患者治疗反应性的价值。结果:100例研究对象中,缓解组患者72例(72.00%),未缓解组患者28例(28.00%),两组性别、年龄比较无统计学差异(均P>0.05),但缓解组患者肿瘤直径小于未缓解组,NKG2A、PD-L1/CD4+和PD-L1/CD8+表达水平均低于未缓解组(均P<0.05)。膀胱癌患者NKG2A、PD-L1/CD4+和PD-L1/CD8+表达预测免疫治疗后缓解的AUC值分别为0.771、0.724、0.710; 联合诊断的AUC为0.836。72例缓解患者中,出现复发29例(40.28%),未出现复发43例(59.72%),两组性别、年龄以及肿瘤直径比较无统计学差异(均P>0.05),但复发组NKG2A、PD-L1/CD4+和PD-L1/CD8+表达水平均高于未复发组(均P<0.05)。NKG2A、PD-L1/CD4+和PD-L1/CD8+表达预测膀胱癌患者缓解后复发的AUC值分别为0.775、0.740、0.728; 联合诊断的AUC为0.874。结论:NKG2A、PD-L1/CD4+和PD-L1/CD8+在不同治疗反应性肌层浸润性膀胱癌患者外周血中表达水平不同,三者对于膀胱癌患者PD-L1阻断免疫治疗反应性均有一定的预测价值,且三者联合预测效能最佳。
Abstract:
Objective:To explore the value of natural killer cell group 2 member A(NKG2A)and Programmed death factor ligand 1(PD-L1)expression in predicting the responsiveness of PD-L1 blocking immunotherapy for myometrial invasive bladder cancer.Methods:A total of 100 patients with myometrial invasive bladder cancer were selected as the research objects.After PD-L1 blocking immunotherapy,they were divided into remission group and non-remission group according to the response to treatment.The patients in remission group were followed up for 3 months,and they were divided into recurrence group and non-recurrence group.The expression levels of NKG2A and PD-L1 on CD4+ and CD8+ cells were compared between the two groups.The ROC curve was used to analyze the value of NKG2A and PD-L1 in predicting the treatment response of patients with bladder cancer.Results:Among the 100 patients,72 patients(72.00%)were in the remission group and 28 patients(28.00%)were in the non-remission group.There was no significant difference in gender and age between the two groups(all P>0.05),but the tumor diameter of patients in the remission group was smaller than that in the non-remission group,and the expression levels of NKG2A,PD-L1/CD4+ and PD-L1/CD8+ were lower than those in the non-remission group(all P<0.05).The AUC values predicted by NKG2A,PD-L1/CD4+ and PD-L1/CD8+ expression in bladder cancer patients after immunotherapy were 0.771,0.724 and 0.710,respectively,and the AUC of combined diagnosis was 0.836.Of the 72 patients with remission,29(40.28%)had recurrence and 43(59.72%)had no recurrence.There was no significant difference between the two groups in gender,age and tumor diameter(all P>0.05),but the expression levels of NKG2A,PD-L1/CD4+ and PD-L1/CD8+ in the recurrent group were higher than those in the non-recurrent group(all P<0.05).The AUC values of NKG2A,PD-L1/CD4+ and PD-L1/CD8+ expression in predicting the recurrence of bladder cancer patients after remission were 0.775,0.740 and 0.728,and the AUC of combined diagnosis was 0.874.Conclusion:NKG2A,PD-L1/CD4+ and PD-L1/CD8+ have different levels of expression in the peripheral blood of patients with different treatment responsive myometrial invasive bladder cancer.The three have a certain predictive value for PD-L1 blocking immune therapy responsiveness of patients with bladder cancer,and the combined prediction effect of the three is the best.

参考文献/References:

[1] DOBRUCH J,OSZCZUDLOWSKI M.Bladder cancer:Current challenges and future directions[J].Medicina(Kaunas),2021,57(8):749.
[2] 梁锐,李蕾蕾,王志强.肿瘤浸润性淋巴细胞在实体瘤的临床研究进展[J].中国肿瘤临床,2021,48(22):1168-1172.
[3] 杨芙蓉,张雨婷,陈志鹏,等.肿瘤代谢介导的免疫逃逸及血管生成研究进展[J].中国药理学通报,2021,37(6):756-760.
[4] ZHOU L,XU B,LIU Y,et al.Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer[J].Oncoimmunology,2021,10(1):1915574.
[5] 张凡,李彦佑,史正奇,等.PD-1/PD-L1抑制剂治疗膀胱癌的研究进展[J].中华外科杂志,2021,59(11):952-955.
[6] COURAU T,BONNEREAU J,CHICOTEAU J,et al.Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment[J].J Immunother Cancer,2019,7(1):74.
[7] YEONG J,SUTEJA L,SIMONI Y,et al.Intratumoral CD39+CD8+T cells predict response to programmed cell death protein-1 or programmed death ligand-1 blockade in patients with NSCLC[J].J Thorac Oncol,2021,16(8):1349-1358.
[8] MINATO H,KATAYANAGI K,KURUMAYA H,et al.Verification of the eighth edition of the UICC-TNM classification on surgically resected lung adenocarcinoma:Comparison with previous classification in a local center[J].Cancer Reports(Hoboken NJ),2021,5(1):1422.
[9] 李辉章,郑荣寿,杜灵彬,等.中国膀胱癌流行现状与趋势分析[J].中华肿瘤杂志,2021,43(3):293-298.
[10] 焦向宁,董维平,路璐,等.浅表性膀胱癌经尿道膀胱癌等离子电切术治疗后患者氧化应激反应水平与疼痛相关性研究[J].陕西医学杂志,2023,52(1):32-35.
[11] 冯国伟,宋鸽,张振庭,等.新辅助免疫联合用于治疗肌层浸润性膀胱癌的研究进展[J].中华泌尿外科杂志,2022,43(4):309-312.
[12] 施鸿金,张劲松,李宁,等.新型免疫检查点抑制剂在膀胱癌中的应用研究进展[J].山东医药,2021,61(26):93-95.
[13] 胡岚萍,邱大胜.恶性肿瘤免疫治疗疗效影像学评估现状[J].肿瘤防治研究,2021,48(12):1118-1122.
[14] 张薇,杨丽颖,孙菊杰,等.PD-1/CD8和PD-L1/CD8肿瘤浸润性淋巴细胞联合评估对早期NSCLC复发的预测价值[J].中华肿瘤防治杂志,2022,29(8):564-570.
[15] 蒋燕,朱鹏飞.参芪地黄汤联合缬沙坦对慢性肾小球肾炎患者细胞免疫和炎症反应的影响[J].陕西中医,2023,44(1):72-75.
[16] LEONE R D,ZHAO L,ENGLERT J M,et al.Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion[J].Science,2019,366(6468):1013-1021.
[17] 胡唯伟,杨大松.肿瘤中PD-L1表达调控的分子机制研究进展[J].中国免疫学杂志,2021,37(21):2634-2639.
[18] 贾方,王秋月,崔文静,等.金复康口服液对Lewis肺癌荷瘤小鼠PD-1、PD-L1表达及相关免疫因子的影响[J].陕西中医,2020,41(10):1347-1350,1417.
[19] 刘小多,徐玉清.循环外泌体PD-L1表达水平与PD-1/PD-L1抑制剂治疗恶性肿瘤疗效的相关性研究现状[J].现代肿瘤医学,2020,28(19):3454-3456.
[20] 赵鹏,刘冬,兰飞,等.非小细胞肺癌化疗前后血清糖类抗原125、基质金属蛋白酶-9、可溶性程序性死亡配体1水平变化及其与疗效关系研究[J].陕西医学杂志,2022,51(12):1564-1567.
[21] 景琼,吴金平,王光亚.miR-34a、PD-1、PD-L1在膀胱癌中的表达及其与预后的相关性分析[J].医学综述,2019,25(20):4133-4138.
[22] YAN S,ZENG H,JIN K,et al.NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer[J].J Immunother Cancer,2022,10(5):4569.
[23] 阿卜杜艾尼?啊卜力孜,排组拉沙拉依阿当,塔来提?吐尔干,等.多房棘球蚴虫体蛋白介导NK细胞表面受体NKG2A对NK细胞功能的影响[J].中国寄生虫学与寄生虫病杂志,2022,40(1):36-42.
[24] 王立韬,白丽.NK细胞免疫负性调节分子及其抗肿瘤作用[J].细胞与分子免疫学杂志,2021,37(11):1045-1050.
[25] 马名扬,原翔,刘怡文,等.CD8+T淋巴细胞表面抑制性受体NKG2A高表达在肺腺癌组织中的临床研究[J].中国医药导报,2020,17(18):15-18,27.

相似文献/References:

[1]林 晨,刘湘鄂,吴天玉 ,等.尾型同源盒转录因子2和同源框蛋白A9在膀胱癌组织中的表达及临床意义*[J].陕西医学杂志,2019,(8):972.
　LIN Chen,LIU Xiange,WU Tianyu,et al.Expressions of CDX2 and HOXA9 in bladder cancer and their relationships with prognosis[J].,2019,(2):972.

备注/Memo

备注/Memo:
基金项目:陕西省自然科学基础研究计划一般项目(青年)(2021JQ-908)
更新日期/Last Update: 2024-02-05